Loading...
For postmenopausal women with advanced, hormone receptor–positive breast cancer, many endocrine treatment options are available. Clinical practice guidelines have long recommended that endocrine therapy should be continued until disease becomes refractory, endocrine options are exhausted, or disease tempo and extent change appreciably. In the latter case, a switch to chemotherapy can be a better therapeutic strategy. Researchers now report the long-term results of a European phase II multicenter trial in which the efficacy and tolerability of fulvestrant (Faslodex), an estrogen-receptor antagonist, were evaluated in women with hormone receptor–positive tumors whose disease had progressed.
Two groups of patients were enrolled prospectively: 7…